Vistagen Announces Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
Portfolio Pulse from Benzinga Newsdesk
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company, announced that PH80, one of its investigational neuroactive nasal sprays, showed statistically significant improvement versus placebo in a Phase 2A study for acute management of the symptoms of premenstrual dysphoric disorder (PMDD).
September 12, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen's PH80 nasal spray showed promising results in a Phase 2A study for PMDD symptoms management, which could potentially boost the company's stock.
Positive clinical trial results often lead to increased investor confidence and can drive up a company's stock price. Given that Vistagen's PH80 nasal spray showed significant improvement in managing PMDD symptoms, this could potentially lead to a rise in VTGN's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100